How to book a medical appointment in Shanghai?

You can book through our online form, email, WeChat, or live chat. We will arrange the appointment within 24 hours and provide full assistance throughout your medical journey.

What languages do you support?

We provide full support in English, Russian, Chinese, Korean, and Japanese. All medical translations are handled by professional medical interpreters.

What are the payment methods?

Medical fees are paid directly to the hospital. Service fees can be paid via bank transfer, WeChat Pay, Alipay, or international wire transfer.

Do you help with visa arrangements?

Yes, we provide complete visa guidance and invitation letters for medical tourism to China.

Which hospitals do you partner with?

We partner with top-tier hospitals in Shanghai including Jiahui International Hospital, Huashan Hospital, Ruijin Hospital, and other leading medical institutions.

Leukemia Treatment in Shanghai: 2026 International Patient Guide

Shanghai Hematology Leadership

Shanghai is China's hematology capital. Ruijin Hospital's Shanghai Institute of Hematology (上海血液学研究所), led by Profs. Wang Zhenyi (王振义, academician) and Chen Zhu (陈竺), pioneered APL (acute promyelocytic leukemia) differentiation therapy using all-trans retinoic acid (ATRA) + arsenic trioxide — now the global cure standard.

Top Hospitals

Ruijin Hospital / Shanghai Institute of Hematology — Global APL pioneer; Prof. Li Junmin (李军民) for leukemia immunotherapy and geriatric hematology.

Changhai Hospital — Prof. Wang Jianmin (王健民), leukemia and hematopoietic stem cell transplant; former Chinese Society of Hematology vice-chair.

FUSCC — CAR-T for B-ALL; comprehensive lymphoma/leukemia program.

Shanghai General Hospital — Bone marrow transplant program.

Subtype Treatment

APL (M3): ATRA + arsenic trioxide — cure rate >90% (Shanghai protocol now global standard).

AML (non-M3): Intensive induction (7+3), hypomethylating agents + venetoclax for elderly/unfit; allogeneic HSCT in first remission for high-risk.

ALL (adult): Pediatric-inspired regimens; CAR-T (tisagenlecleucel or domestic equivalents) for relapsed/refractory B-ALL bridging to transplant.

CML: Tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, ponatinib); domestic generics very affordable.

CLL: BTK inhibitors (zanubrutinib, orelabrutinib — Chinese-developed), BCL2 inhibitor (venetoclax).

Bone Marrow Transplant

Changhai Hospital and Ruijin Hospital have major HSCT programs. Unrelated donor searches through China Marrow Donor Program (CMDP) or haploidentical family donors are both supported.

Cost Reference

APL treatment: ¥100,000–200,000 total (curative). AML induction/consolidation: ¥200,000–400,000. Allogeneic HSCT: ¥400,000–800,000. CAR-T for B-ALL: ¥1,000,000+. CML TKI therapy: ¥3,000–15,000/month (domestic generics at lower end).